Micke O - Search Results

1

Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?

Eich HT, Müller RP, Micke O, Kocher M, Berthold F, Hero B. Eich HT, et al. Among authors: micke o. Strahlenther Onkol. 2005 Jun;181(6):378-84. doi: 10.1007/s00066-005-1362-2. Strahlenther Onkol. 2005. PMID: 15925980

2

[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].

Wagner W, von Eiff M, Klinke F, Micke O, Rübe C, Willich N. Wagner W, et al. Among authors: micke o. Strahlenther Onkol. 1995 Jul;171(7):390-7. Strahlenther Onkol. 1995. PMID: 7631260 Clinical Trial. German.

3

[Treatment results of soft tissue sarcomas in adults].

Wagner W, Willich N, Rübe C, Prott FJ, Micke O. Wagner W, et al. Among authors: micke o. Strahlenther Onkol. 1994 Feb;170(2):91-9. Strahlenther Onkol. 1994. PMID: 8108787 German.

4

[Dosimetry methods in determining radiation dosage of the rectum in HDR-brachytherapy of cervix carcinoma].

Eich HT, Haverkamp U, Micke O, Prott FJ, Pötter R. Eich HT, et al. Among authors: micke o. Strahlenther Onkol. 1998 Jul;174(7):375-80. doi: 10.1007/BF03038352. Strahlenther Onkol. 1998. PMID: 9689959 German.

5

Diagnostic radiation oncology: malignant cystosarcoma phylloides.

Eich PD, Diederich S, Eich HT, Micke O, Wagner W. Eich PD, et al. Among authors: micke o. Strahlenther Onkol. 2000 Apr;176(4):192-5. doi: 10.1007/s000660050056. Strahlenther Onkol. 2000. PMID: 10812393

6

Dosimetric analysis at ICRU reference points in HDR-brachytherapy of cervical carcinoma.

Eich HT, Haverkamp U, Micke O, Prott FJ, Müller RP. Eich HT, et al. Among authors: micke o. Rontgenpraxis. 2000;53(2):62-6. Rontgenpraxis. 2000. PMID: 10994367

7

Radiotherapy of esthesioneuroblastoma.

Eich HT, Staar S, Micke O, Eich PD, Stützer H, Müller R. Eich HT, et al. Among authors: micke o. Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):155-60. doi: 10.1016/s0360-3016(00)00811-7. Int J Radiat Oncol Biol Phys. 2001. PMID: 11163509

8

Microscopic residual disease is a risk factor in the primary treatment of breast cancer.

Schuck A, Könemann S, Heinen K, Rübe CE, Hesselmann S, Reinartz G, Schüller P, Micke O, Schäfer U, Willich N. Schuck A, et al. Among authors: micke o. Strahlenther Onkol. 2002 Jun;178(6):307-13. doi: 10.1007/s00066-002-0950-7. Strahlenther Onkol. 2002. PMID: 12122786

9

Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma.

Eich HT, Eich D, Micke O, Süttzer H, Casper C, Krieg T, Müller RP. Eich HT, et al. Among authors: micke o. Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):899-906. doi: 10.1016/s0360-3016(02)04199-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 12605967

10

Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma.

Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, Berthold F, Müller RP. Eich HT, et al. Among authors: micke o. Strahlenther Onkol. 2003 Apr;179(4):233-40. doi: 10.1007/s00066-003-1089-x. Strahlenther Onkol. 2003. PMID: 12707712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters